- Indivior said Tuesday it would discuss its strategy and contingency plans in a December conference call after a US court allowed rival Dr. Reddy's Laboratories to sell a generic version of the company's opioid addiction treatment.

The company said it would provide updates during the call, slated for 18 December, on full-year performance including Sublocade, a once-a-month injectable drug to treat opioid addiction.

At 8:12am: [LON:INDV] Indivior Plc share price was -1.02p at 99.88p

Story provided by